The positive versus negative distinction of schizophrenic disorders has pro moted ongoing research. Phenomenology, psychopathology, biology, genet ics, pharmacological and nonpharmacological treatment, psychosocial and longitudinal research: all have found a new focus of interest. This volume attempts to provide an unbiased picture of the status of American and Eu ropean knowledge regarding the positive/negative distinction. Researchers from North America and Europe describe the relation of modern concepts of positive and negative symptomatology to the original models of Rey nolds and Jackson. Integrating phenomenological, genetic, and biological factors, the authors depict current methods of assessing positive and nega tive symptomatology, differentiating between primary and secondary symp tomatology, and using pharmacological and nonpharmacological treatment. The stability of positive and negative symptoms over time and evidence for the occurrence of separate positive and negative episodes over a long-term course of schizophrenia are extensively discussed in terms of their implica tions on the positive/negative construct. The relevance of the positive/nega tive dichotomy to child and adolescent schizophrenia is also debated. The main aim of this book is not to advocate a single concept and present only arguments supporting it, but to discuss important controversies. Prob lems concerning a concept cannot be solved by ignoring them. However, unanswered questions may be resolved through discussion, debate, and con structive compromise.

Schizophrenia: The Facts provides a concise and up-to-date account of the underlying causes and symptoms of schizophrenia, as well as current theories about the disorder. The book provides a welcome source of information and advice both for families of schizophrenics and those involved in caring for them.

First published in 1991. Routledge is an imprint of Taylor & Francis, an informa company.

Schizophrenia is one of the most severe psychiatric disorders, carrying with it significant stigma and a number of debilitating symptoms. While material on its "positive" symptoms, such as hallucinations and delusions, is readily available, its "negative" symptoms, which present heterogeneously as deficits across a variety of domains, are not nearly so well-documented and often go undiagnosed with no effective treatment. Given the poor functioning and outcomes which occur as a result of these symptoms, it is imperative they receive greater focus. Part of the Oxford Psychiatry Library (OPL) series, this concise pocketbook provides readers with a comprehensive overview of the definition, evaluation, and treatment of negative symptoms. Written by experts in the field, with key points at the beginning of each chapter for quick reference, this is an invaluable resource for any mental health care professional working with individuals affected by schizophrenia.

Estimates indicate that as many as 1 in 4 Americans will experience a mental health problem or will misuse alcohol or drugs in their lifetimes. These disorders are among the most highly stigmatized health conditions in the United States, and they remain barriers to full participation in society in areas as basic as education, housing, and employment. Improving the lives of people with mental health and substance abuse disorders has been a priority in the United States for more than 50 years. The Community Mental Health Act of 1963 is considered a major turning point in America's efforts to improve behavioral healthcare. It ushered in an era of optimism and hope and laid the groundwork for the consumer movement and new models of recovery. The consumer movement gave voice to people with mental and substance use disorders and brought their perspectives and experience into national discussions about mental health. However over the same 50-year period, positive change in American public attitudes and beliefs about mental and substance use disorders has lagged behind these advances. Stigma is a complex social phenomenon based on a relationship between an attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination. This report contributes to national efforts to understand and change attitudes, beliefs and behaviors that can lead to stigma and discrimination. Changing stigma in a lasting way will require coordinated efforts, which are based on the best possible evidence, supported at the national level with multiyear funding, and planned and implemented by an effective coalition of representative stakeholders. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change explores stigma and discrimination faced by individuals with mental or substance use disorders and recommends effective strategies for reducing stigma and encouraging people to seek treatment and other supportive services. It offers a set of conclusions and recommendations about successful stigma change strategies and the research needed to inform and evaluate these efforts in the United States.

An international team of leading researchers and clinicians provides the first comprehensive, epidemiological overview of this multi-faceted and still-perplexing disorder. Controversial issues such as the validity of discrete or dimensional classifications of schizophrenia and the continuum between psychosis and 'normality' are explored in depth. Separate chapters are devoted to topics of particular relevance to schizophrenia such as suicide, violence and substance abuse. Finally, new prospects for treatment and prevention are considered.

While there are a number of books on positive psychology, Positive Psychiatry is unique in its biological foundation and medical rigor and is the only book designed to bring positive mental health ideas and interventions into mainstream psychiatric research, training, and clinical practice. After an overview describing the definition, history, and goals of positive psychiatry, the contributors—pioneers and thought leaders in the field—explore positive psychosocial factors, such as resilience and psychosocial growth; positive outcomes, such as recovery and well-being; psychotherapeutic and behavioral interventions, among others; and special topics, such as child and geriatric psychiatry, diverse populations, and bioethics. The book successfully brings the unique skill sets and methods of psychiatry to the larger positive health movement. Each chapter highlights key points for current clinical services, as practiced by psychiatrists, primary care doctors, and nurses, as well as those in allied health and mental health fields. These readers will find Positive Psychiatry to be immensely helpful in bringing positive mental health concepts and interventions into the clinical arena.

In line with other volumes in the Neuroscience Perspectives Series, this volume covers the background, pharmacology, molecular biology, and biochemistry of antipsychotic drugs, together with an overview assessment of the therapeutic considerations. Over the past 40 years, the effectiveness of conventional neuroleptic agents for psychotic illness has been offset by a wide range of adverse side-effects, including motor side-effects like parkinsonism. Studies show that lowering doses may still produce the antipsychotic effect while lessening the risk of side-effects. As all available antispychotic drugs are able to block dopamine, specifically D2 receptors, doses below the threshold level for producing acute motor disorder can still be therapeutically effective. With the identification and characterization of multiple dopamine receptors, the possibility of more selective drugs with better side-effect potential has arisen. Other novel antipsychotic agents include D1 receptor blockers, partial dopamine agonists and non-dopamine drugs such as 5-HT receptor blockers, sigma receptor antagonists and NMDA receptor agonists. This volume reviews both the basic science of the conventional and atypical neuroleptics and their present and potential therapeutic use.